NP-1815-PX

• Description :

  NP-1815-PX is a potent and selective P2X4R antagonist. NP-1815-PX has anti-inflammatory activity, and can relieve pain in chronic pain models. NP-1815-PX also inhibits guinea pig tracheal/bronchial smooth muscle (TSM and BSM) contractions[1][2][3].

• UNSPSC :

  12352005

• Target :

  P2X Receptor

• Type :

  Reference compound

• Related Pathways :

  Membrane Transporter/Ion Channel

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Inflammation/Immunology; Neurological Disease

• Assay Protocol :

  https://www.medchemexpress.com/np-1815-px.html

• Solubility :

  10 mM in DMSO

• Smiles :

  O=C1NC2=C(N(C(C1)=O)C3=CC=CC(C4=NOC(N4)=S)=C3)C=CC5=C2C=CC=C5

• Molecular Formula :

  C21H14N4O3S

• Molecular Weight :

  402.43

• References & Citations :

  [1]Matsumura Y, et al. A novel P2X4 receptor-selective antagonist produces anti-allodynic effect in a mouse model of herpetic pain. Sci Rep. 2016 Aug 31;6:32461.|[2]Obara K, et al. Effects of NP-1815-PX, a P2X4 Receptor Antagonist, on Contractions in Guinea Pig Tracheal and Bronchial Smooth Muscles. Biol Pharm Bull. 2022;45 (8) :1158-1165.|[3]D'Antongiovanni V, et al. Anti-inflammatory Effects of Novel P2X4 Receptor Antagonists, NC-2600 and NP-1815-PX, in a Murine Model of Colitis. Inflammation. 2022 Aug;45 (4) :1829-1847.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [1239578-79-0]